Abl Bio Inc.

Yuhan Corporation

Legochem Biosciences, Inc.

Donghoon Yeom

Yangsoon Lee

Kyungjin Park

Juhee Kim

Bora Lee

Yeunju Kim

Hyejin Chung

Byungje Sung

Kyeongsu Park

Jinhyung Ahn

Daehae Song

Jiseon Yoo

Eunyoung Park

Eunsil Sung

Youngdon Pak

Eun-Jung Lee

Yong-Gyu Son

Jaehyun Eom

Jinwon Jung

Seawon Ahn

Eunjung Kim

Ui-Jung Jung

Dongin Kim

Sang Hoon Lee

Yong Zu Kim

Ho Young Song

Ju Young Lee

Jeiwook Chae

Sung Min Kim

Moo Young Song

Hyoung Rae Kim

Kyung Eun Park

Chang Sun Lee

Dae Hyuck Kang

Jaeho Jung

Na Rae Lee

Ji Hye Oh

Yun-Hee Park

Youngkwang Kim

Hyeun Joung Lee

Minji Park

Young Bong Park

Sungwon An

Hyun Min Ryu

Yeryoung Yong

Wonjun Son

JinWon Jung

Taewang Kim

Youngeun Hong

Weonkyoo You

Mikyung Chang

Jaehyoung Jeon

Junhyun Jeong

Ju Yuel Baek

Young-Jae Yang

Yoseob Lee

Chanmoo Lee

Nara Han

Junghyeon Hong

Ji-Na You

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Anti-BCMA antibody and use thereof

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

Growing community of inventors

Seongnam-si, South Korea

Donghoon Yeom